Characterization of protective epitopes in a highly conserved Plasmodium falciparum antigenic protein containing repeats of acidic and basic residues

The delineation of putatively protective and immunogenic epitopes in vaccine candidate proteins constitutes a major research effort towards the development of an effective malaria vaccine. By virtue of its role in the formation of the immune clusters of merozoites, its location on the surface of merozoites, and its highly conserved nature both at the nucleotide sequence level and the amino acid sequence level, the antigen which contains repeats of acidic and basic residues (ABRA) of the human malaria parasite Plasmodium falciparum represents such an antigen. Based upon the predicted amino acid sequence of ABRA, we synthesized eight peptides, with six of these (AB-1 to AB-6) ranging from 12 to 18 residues covering the most hydrophilic regions of the protein, and two more peptides (AB-7 and AB-8) representing its repetitive sequences. We found that all eight constructs bound an appreciable amount of antibody in sera from a large proportion of P. falciparum malaria patients; two of these peptides (AB-1 and AB-3) also elicited a strong proliferation response in peripheral blood mononuclear cells from all 11 human subjects recovering from malaria. When used as carrier-free immunogens, six peptides induced a strong, boostable, immunoglobulin G-type antibody response in rabbits, indicating the presence of both B-cell determinants and T-helper-cell epitopes in these six constructs. These antibodies specifically cross-reacted with the parasite protein(s) in an immunoblot and in an immunofluorescence assay. In another immunoblot, rabbit antipeptide sera also recognized recombinant fragments of ABRA expressed in bacteria. More significantly, rabbit antibodies against two constructs (AB-1 and AB-5) inhibited the merozoite reinvasion of human erythrocytes in vitro up to ∼90%. These results favor further studies so as to determine possible inclusion of these two constructs in a multicomponent subunit vaccine against asexual blood stages of P. falciparum

Characterization of protective epitopes in a highly conserved Plasmodium falciparum antigenic protein containing repeats of acidic and basic residues

The delineation of putatively protective and immunogenic epitopes in vaccine candidate proteins constitutes a major research effort towards the development of an effective malaria vaccine. By virtue of its role in the formation of the immune clusters of merozoites, its location on the surface of merozoites, and its highly conserved nature both at the nucleotide sequence level and the amino acid sequence level, the antigen which contains repeats of acidic and basic residues (ABRA) of the human malaria parasite Plasmodium falciparum represents such an antigen. Based upon the predicted amino acid sequence of ABRA, we synthesized eight peptides, with six of these (AB-1 to AB-6) ranging from 12 to 18 residues covering the most hydrophilic regions of the protein, and two more peptides (AB-7 and AB-8) representing its repetitive sequences. We found that all eight constructs bound an appreciable amount of antibody in sera from a large proportion of P. falciparum malaria patients; two of these peptides (AB-1 and AB-3) also elicited a strong proliferation response in peripheral blood mononuclear cells from all 11 human subjects recovering from malaria. When used as carrier-free immunogens, six peptides induced a strong, boostable, immunoglobulin G-type antibody response in rabbits, indicating the presence of both B-cell determinants and T-helper-cell epitopes in these six constructs. These antibodies specifically cross-reacted with the parasite protein(s) in an immunoblot and in an immunofluorescence assay. In another immunoblot, rabbit antipeptide sera also recognized recombinant fragments of ABRA expressed in bacteria. More significantly, rabbit antibodies against two constructs (AB-1 and AB-5) inhibited the merozoite reinvasion of human erythrocytes in vitro up to ~90%. These results favor further studies so as to determine possible inclusion of these two constructs in a multicomponent subunit vaccine against asexual blood stages of P. falciparum

Role of H- and D- MATE-Type Transporters from Multidrug Resistant Clinical Isolates of Vibrio fluvialis in Conferring Fluoroquinolone Resistance

Background: The study seeks to understand the role of efflux pumps in multidrug resistance displayed by the clinical isolates of Vibrio fluvialis, a pathogen known to cause cholera-like diarrhoea. Methodology: Two putative MATE family efflux pumps (H- and D-type) were PCR amplified from clinical isolates of V. fluvialis obtained from Kolkata, India, in 2006 and sequenced. Bioinformatic analysis of these proteins was done to predict protein structures. Subsequently, the genes were cloned and expressed in a drug hypersusceptible Escherichia coli strain KAM32 using the vector pBR322. The recombinant clones were tested for the functionality of the efflux pump proteins by MIC determination and drug transport assays using fluorimeter. Results: The sequences of the genes were found to be around 99 % identical to their counterparts in V. cholerae. Protein structure predicting servers TMHMM and I-TASSER depicted ten-twelve membrane helical structures for both type of pumps. Real time PCR showed that these genes were expressed in the native V. fluvialis isolates. In the drug transport assays, the V. fluvialis clinical isolates as well as recombinant E. coli harbouring the efflux pump genes showed the energydependent and sodium ion-dependent drug transport activity. KAM32 cells harbouring the recombinant plasmids showed elevated MIC to the fluoroquinolones, norfloxacin and ciprofloxacin but H-type pumps VCH and VFH from V. cholerae and V. fluvialis respectively, showed decreased MIC to aminoglycosides like gentamicin, kanamycin and streptomycin. Decrease i

2D and 3D structure predictions of H- and D- type MATE pumps.

<p><b>A and C.</b> Schematic representation of the predicted secondary structure of VFD and VFH respectively. The topology was predicted based on the algorithm TMHMM Server 2.0. <b>B and D.</b> Schematic representation of the predicted 3D structure of VFD and VFH respectively. The topology was predicted based on the algorithm I-TASSER.</p

Involvement of recombinant efflux pumps in the transport of various compounds.

<p><b>A.</b> VCD-induced efflux of norfloxacin from recombinant <i>E. coli</i> harbouring <i>vcd</i> gene. pBR322: Accumulation of norfloxacin in KAM32 cells transformed with <i>pBR322</i> empty vector, VCD: Accumulation of norfloxacin in KAM32 cells transformed with <i>pBR322-vcd</i>. *, the values of fluorescence for VCD were significantly different for as compared to pBR322 control (<i>P</i><0.05). <b>B.</b> Accumulation of ethidium bromide in cells transformed with <i>pBR322</i> empty vector (pBR), <i>pBR322-vcd</i> (VCD), <i>pBR322-vfd</i> (VFD), <i>pBR322-vch</i> (VCH) and <i>pBR322-vfh</i> (VFH) *, the values of fluorescence for VFH were significantly different as compared to pBR322 control (<i>P</i><0.05). For other recombinants it was significantly different at either of indicated time points (<i>P</i><0.05).</p

Minimum inhibitory concentrations (MICs) for recombinant clones carrying MATE-type efflux pump genes from <i>V. fluvialis</i> and <i>V. cholerae</i>.

<p>VCH and VCD : pBR322 recombinant clones carrying H- and D- MATE pump genes from <i>V. cholerae</i> N16961.</p><p>VFH and VFD : pBR322 recombinant clones carrying H- and D- MATE pump genes from a clinical isolate of <i>V. fluvialis</i>.</p

Sodium-ion dependence of recombinant efflux pumps

<p>Induction of norfloxacin efflux in the presence of 100 mM sodium chloride (+NaCl) or 100 mM potassium chloride (+KCl) in the <i>E. coli</i> KAM32 cells transformed with <b>A.. </b><i>pBR322</i> or <b>B.. </b><i>pBR322-vfh</i>. <b>C.</b> Effect of increase in Sodium ion concentration on the efflux pump activity of VFH. *, The activity of VFH in the presence of 100 mM and 200 mM NaCl was significantly different from that of the control without NaCl (<i>P</i><0.05).</p

Plasmodium berghei Merozoite surface protein-9: immunogenicity and protective efficacy using a homologous challenge model

Merozoite surface protein-9 (MSP-9) from Plasmodium is considered a promising vaccine candidate due to its location and possible role in erythrocyte invasion. We report the identification and characterization of Plasmodium berghei MSP-9 (PbMSP-9) and its properties as an immunogen using a recombinant PbMSP-9 fragment to immunize BALB/c mice. PbMSP-9 was found to harbor erythrocyte binding and serine protease activity. PbMSP-9 formulation in alum was highly immunogenic in BALB/c mice. To evaluate the protective efficacy, immunized mice were submitted to homologous challenge with P. berghei NK65 blood-stage parasites. Protection against the parasite challenge was observed in BALB/c mice immunized with the PbMSP-9 formulation. These results suggest for the first time that MSP-9 based immunogens may constitute part of an effective malaria vaccine

Immunogenicity of recombinant fragments of Plasmodium falciparum acidic basic repeat antigen produced in Escherichia coli

The acidic basic repeat antigen (ABRA) of Plasmodium falciparum is a potential vaccine candidate against erythrocytic stages of malaria. We report, for the first time, the immunological characteristics of recombinant ABRA constructs. The recombinant proteins representing different fragments of ABRA were expressed in Escherichia coli, either as fusions with maltose binding protein or as 6X histidine tagged molecules, and purified by affinity chromatography. Immunogenicity studies with these constructs in rabbits and mice indicated that the N-terminal region is the least immunogenic part of ABRA. T-cell proliferation experiments in mice immunized with these constructs revealed that the T-cell epitopes were localized in the middle portion of the protein. More importantly, the purified immunoglobulin G specific to middle and C-terminal fragments prevented parasite growth at levels approaching 80-90%. We found that these proteins were also recognized by sera from P. falciparum-infected patients from Rourkela, a malaria endemic zone of India. Our immunogenicity results suggest that potential of ABRA as a vaccine candidate antigen should be investigated further

Expression and characterisation of Plasmodium falciparum acidic basic repeat antigen expressed in Escherichia coli

The acidic basic repeat antigen (ABRA) of Plasmodium falciparum has been localised on the merozoite surface and in the parasitophorous vacuole. It is one of the antigens enriched in the clusters of merozoites formed with growth inhibitory immune serum and possesses chymotrypsin-like activity. Chymostatin, an inhibitor of chymotrypsin, inhibits malaria invasion as well as autoproteolysis of ABRA. Based on these characteristics of ABRA, it seems important for invasion and should be investigated as a target for vaccine and drug design. For the functional characterisation of this protein, the full-length mature ABRA protein and its fragments with/without the putative protease active site were cloned, expressed and purified from Escherichia coli. The polyclonal serum raised against recombinant ABRA fragment recognised a parasite protein with a mobility of 101 kDa in an immunoblot assay and showed immunofluorescence activity with a schizont-rich preparation of P. falciparum. Using a partially purified fragment containing the putative active site and fluorogenic and chromogenic substrates, we established that the protease activity of ABRA resides in the N-terminal portion of the protein and the highly charged C-terminal part of the protein is not required for this activity. The protease activity of ABRA was inhibited with serine protease inhibitors like chymostatin and phenyl methyl sulfonyl fluoride (PMSF) whereas leupeptin was not able to inhibit this enzyme activity. These results clearly indicated that ABRA is a protease with chymotrypsin-like specificity. This is the first report describing the expression and characterisation of recombinant ABRA protein